BOSTON BIOPHARMA, INC. – Trademark Portfolio
Entity Type: 03
BOSTON BIOPHARMA, INC. holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 12 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 5 trademarks are registered and 1 is pending. Notable registered marks include BB RAPID, BOSTOFLURANE, BOSTON BIOPHARMA, and TRANSFORMATION FOR LIFE. The owner is based in NEWARK, DE.
113 BARKSDALE PROFESSIONAL CENTER
NEWARK, DE 19711
Showing of trademarks Trademarks
Trademark Classifications
BOSTON BIOPHARMA, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BOSTON BIOPHARMA, INC. have?
BOSTON BIOPHARMA, INC. has 15 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 pending, 2 abandoned, 7 cancelled.
What trademark classes does BOSTON BIOPHARMA, INC. file in?
BOSTON BIOPHARMA, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are BOSTON BIOPHARMA, INC.'s most well-known trademarks?
BOSTON BIOPHARMA, INC.'s registered trademark portfolio includes well-known marks such as BB RAPID, BOSTOFLURANE, BOSTON BIOPHARMA, and TRANSFORMATION FOR LIFE. These are among 5 currently registered trademarks in the portfolio.
What is BOSTON BIOPHARMA, INC.'s trademark registration success rate?
BOSTON BIOPHARMA, INC. has a 36% trademark registration rate, with 5 out of 14 resolved applications resulting in successful registration. Currently, 1 application is pending review.